Drug Trial Radar · NCT00933231
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
281
Actual
Start
Aug 17, 2009
Primary completion
May 11, 2015
Study completion Apr 3, 2018
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Canada, Inc.
- First posted
- Jul 7, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre study examining the use of Advagraf-minimization strategy and/or the use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal allografts.
Conditions
- Kidney Transplantation
Interventions
tacrolimusDrug
Standard dose, Oral
tacrolimusDrug
Low dose, Oral
SimulectBiological
IV
CellceptDrug
Oral
CorticosteroidsDrug
IV and Oral
RamiprilDrug
Oral
IrbesartanDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with the Presence of Allograft Interstitial Fibrosis and Tubular Atrophy (IF/TA) as Assessed at a Central Pathology LabTime frame: up to 24 months
- Progression of IF/TA from Month 6 to Month 24Time frame: up to 24 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site CA133 Foothills Medical Centre
Calgary, Alberta, Canada
Site CA54 University of Alberta Hospital
Edmonton, Alberta, Canada
Site CA141 Health Sciences Centre
Winnipeg, Manitoba, Canada
Site CA114 Capital District Health Authority- QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Site CA150 St. Joseph's Healthcare
Hamilton, Ontario, Canada
Site CA27 London Health Sciences Centre
London, Ontario, Canada
Site CA165 St. Michael's Hospital
Toronto, Ontario, Canada
Site CA238 Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Site CA172 Hôpital Notre-Dame du CHUM
Montreal, Quebec, Canada
Site CA144 McGill University Health Centre
Montreal, Quebec, Canada
Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec
Québec, Quebec, Canada
Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont
Sherbrooke, Quebec, Canada
Site CA142 St. Paul's Hospital
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.